AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8551788 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte and platelet depletion (experimental group)
Number of subjects: 42
Study 8551788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leukocyte and platelet depletion)
Number of subjects: 42
Study 1988778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 50 mg as an intramuscular depot injection every 3 weeks for 1 year
Number of subjects: 79
Study 1988778 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen‐progestogen therapy (2 mg 17 beta‐estradiol plus 1 mg norethisterone acetate) daily for 1 year
Number of subjects: 79
Study 1988778 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 79
Study 1988778 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 79
Study 6216814 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation therapy (MTG)
Number of subjects: 51
Study 6216814 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CTG)
Number of subjects: 51
Study 31860800 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM), n = 20
Number of subjects: 40
Study 31860800 — intervention group
Group type: COMPARATOR
Intervention: Non-NAM treated group, n = 20
Number of subjects: 40
Study 31560580 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitor and an aromatase inhibitor (AI)
Number of subjects: 1827
Study 31560580 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitor (AI) alone
Number of subjects: 1827
Study 29123208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 40
Study 29123208 — intervention group
Group type: COMPARATOR
Intervention: Belatacept (BELA)
Number of subjects: 40
Study 25491882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 59
Study 25491882 — intervention group
Group type: COMPARATOR
Intervention: Nasal intermittent positive pressure ventilation (NIPPV) + very early surfactant treatment
Number of subjects: 59
Study 24570029 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet
Number of subjects: 213
Study 24570029 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 213
Study 22313936 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 64
Study 22313936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20561180 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of melatonin daily
Number of subjects: 8
Study 20561180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17660178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3%/dexamethasone 0.1% (CIP/DEX)
Number of subjects: 0
Study 17660178 — intervention group
Group type: COMPARATOR
Intervention: Neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1.0% (NPH)
Number of subjects: 0
Study 15683857 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% concentrated intravenous gammaglobulin
Number of subjects: 35
Study 15683857 — intervention group
Group type: COMPARATOR
Intervention: 5% concentrated intravenous gammaglobulin
Number of subjects: 35
Study 11866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin in whole gut lavage fluid (WGLF)
Number of subjects: 85
Study 11866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloperoxidase in WGLF
Number of subjects: 85
Study 11866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme in WGLF
Number of subjects: 85
Study 11866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin in WGLF
Number of subjects: 85
Study 11866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability of lactoferrin and myeloperoxidase in WGLF
Number of subjects: 85
Study 11866274 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability of PMN-E and lysozyme in WGLF
Number of subjects: 85
Study 10195822 — intervention group
Group type: EXPERIMENTAL
Intervention: Tridimensional Personality Questionnaire (TPQ)
Number of subjects: 521
Study 8389559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditiocarb (DTC)
Number of subjects: 50
Study 8389559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3040815 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 50 mg before breakfast
Number of subjects: 20
Study 3040815 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg before breakfast
Number of subjects: 20
Study 3040815 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 50 mg with breakfast
Number of subjects: 20
Study 3040815 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg with breakfast
Number of subjects: 20
Study 28447203 — intervention group
Group type: COMPARATOR
Intervention: 400 µg/day folate
Number of subjects: 198
Study 28447203 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 µg/day folate
Number of subjects: 198
Study 27716226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training for staff and youth MHFA training for wider staff body
Number of subjects: 2300
Study 27716226 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support service established in intervention schools
Number of subjects: 2300
Study 27716226 — intervention group
Group type: COMPARATOR
Intervention: Usual practice in control schools
Number of subjects: 2300
Study 24556095 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS)
Number of subjects: 173
Study 24556095 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 173
Study 24556095 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 173
Study 24556095 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients
Number of subjects: 173
Study 22982085 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitalization approach (treatment matched to relative strengths)
Number of subjects: 34
Study 22982085 — intervention group
Group type: COMPARATOR
Intervention: Compensation approach (treatment matched to relative deficits)
Number of subjects: 34
Study 20206314 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet (VLED) (415 kcal/day)
Number of subjects: 192
Study 20206314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) (810 kcal/day)
Number of subjects: 192
Study 20206314 — intervention group
Group type: COMPARATOR
Intervention: Combined groups (VLED and LED)
Number of subjects: 192
Study 17850471 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 26
Study 17850471 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 26
Study 15660025 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (4‐12 mg/d)
Number of subjects: 50
Study 15660025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no candesartan)
Number of subjects: 50
Study 12106837 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy in AMI patients
Number of subjects: 41
Study 10433575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.i.d.
Number of subjects: 85
Study 10433575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg b.i.d.
Number of subjects: 85
Study 10433575 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 85
Study 10433575 — intervention group
Group type: COMPARATOR
Intervention: Clofazimine
Number of subjects: 85
Study 9592273 — intervention group
Group type: EXPERIMENTAL
Intervention: New speech training method, duration 22 to 120 days (average 63 days)
Number of subjects: 50
Study 1747286 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (30 ng kg‐1 min‐1)
Number of subjects: 14
Study 1747286 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion during exercise
Number of subjects: 14
Study 1747286 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study 6174041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol, 300 mg three times daily
Number of subjects: 20
Study 6174041 — intervention group
Group type: COMPARATOR
Intervention: Sustained release quinidine sulfate in identical doses
Number of subjects: 20
Study 31651299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy for 9 weeks
Number of subjects: 197
Study 31651299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy for 9 weeks, adherence to ≥12 treatment sessions
Number of subjects: 197
Study 31651299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy for 9 weeks, adherence to 0-11 treatment sessions
Number of subjects: 197
Study 31651299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy
Number of subjects: 197
Study 31651299 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 197
Study 28803710 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal HPβCD 900 mg
Number of subjects: 14
Study 28803710 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal HPβCD 1200 mg
Number of subjects: 14
Study 28803710 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal HPβCD 600 or 900 mg
Number of subjects: 14
Study 28803710 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal HPβCD
Number of subjects: 14
Study 25575085 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive posterior lumbar interbody fusion (Rom-PLIF)
Number of subjects: 80
Study 25575085 — intervention group
Group type: COMPARATOR
Intervention: Conventional open posterior PLIF using freehand technique
Number of subjects: 80
Study 24191673 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (started at week 0)
Number of subjects: 299
Study 24191673 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART (started when CD4 <15%)
Number of subjects: 299
Study 24191673 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=275)
Number of subjects: 299
Study 21778486 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute risk reduction counseling session
Number of subjects: 0
Study 21778486 — intervention group
Group type: COMPARATOR
Intervention: 20-minute HIV-STI educational session
Number of subjects: 0
Study 18626659 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconscious thought
Number of subjects: 0
Study 18626659 — intervention group
Group type: COMPARATOR
Intervention: Immediate condition
Number of subjects: 0
Study 18626659 — intervention group
Group type: COMPARATOR
Intervention: Conscious thought
Number of subjects: 0
Study 17571652 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 20
Study 17571652 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 20
Study 17571652 — intervention group
Group type: COMPARATOR
Intervention: LASIK vs PRK
Number of subjects: 20
Study 17571652 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast acuity and contrast sensitivity
Number of subjects: 20
Study 15545305 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (dosage not specified)
Number of subjects: 106
Study 11802520 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine 150 mg/day
Number of subjects: 70
Study 11802520 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 9 mg/day
Number of subjects: 70
Study 9556922 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC
Number of subjects: 30
Study 9556922 — intervention group
Group type: EXPERIMENTAL
Intervention: EMIT
Number of subjects: 30
Study 9824170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral group treatment (CBT)
Number of subjects: 32
Study 9824170 — intervention group
Group type: COMPARATOR
Intervention: Interactional group treatment (IT)
Number of subjects: 32
Study 2313529 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxed dental floss
Number of subjects: 200
Study 2313529 — intervention group
Group type: COMPARATOR
Intervention: Unwaxed dental floss
Number of subjects: 200
Study 2313529 — intervention group
Group type: EXPERIMENTAL
Intervention: Different brand of waxed dental floss
Number of subjects: 200
Study 2313529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint flavored waxed floss
Number of subjects: 200
Study 2313529 — intervention group
Group type: COMPARATOR
Intervention: Plain waxed floss
Number of subjects: 200
Study 2313529 — intervention group
Group type: COMPARATOR
Intervention: Neither type of floss
Number of subjects: 200
Study 668973 — intervention group
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide (0.25 mg/cm2 of the skin)
Number of subjects: 30
Study 668973 — intervention group
Group type: COMPARATOR
Intervention: aqua distillata
Number of subjects: 30
Study 30961875 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing Pequeños intervention
Number of subjects: 829
Study 30961875 — intervention group
Group type: COMPARATOR
Intervention: Control group (core curriculum)
Number of subjects: 829
Study 28179226 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grains (WG)
Number of subjects: 81
Study 28179226 — intervention group
Group type: COMPARATOR
Intervention: Refined grains (RG)
Number of subjects: 81
Study 25851287 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics + Vitamin E supplementation (intervention group; n=76)
Number of subjects: 152
Study 25851287 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (control group; n=76)
Number of subjects: 152
Study 23392685 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful heat stimuli
Number of subjects: 0
Study 23392685 — intervention group
Group type: COMPARATOR
Intervention: Auditory stimuli matched for unpleasantness to heat stimuli
Number of subjects: 0
Study 22980098 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (fish oil) supplementation
Number of subjects: 8
Study 19360499 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional occupational therapy with modified right half-field eye-patching for 4 weeks
Number of subjects: 35
Study 19360499 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only for 4 weeks
Number of subjects: 35
Study 17433315 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2.5 g/day
Number of subjects: 56
Study 17433315 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1.5 g/day
Number of subjects: 56
Study 15206693 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB TL01
Number of subjects: 17
Study 15206693 — intervention group
Group type: COMPARATOR
Intervention: Trimethylpsoralen bath PUVA
Number of subjects: 17
Study 11481350 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan followed by 5-FU
Number of subjects: 33
Study 11481350 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan preceded by 5-FU
Number of subjects: 33
Study 11481350 — intervention group
Group type: COMPARATOR
Intervention: Both sequences at identical irinotecan doses
Number of subjects: 33
Study 11481350 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan preceding 5-FU
Number of subjects: 33
Study 9710039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 0
Study 9710039 — intervention group
Group type: COMPARATOR
Intervention: Disease-matched controls
Number of subjects: 0
Study 9710039 — intervention group
Group type: COMPARATOR
Intervention: Nonteratogen controls
Number of subjects: 0
Study 7988343 — intervention group
Group type: EXPERIMENTAL
Intervention: big endothelin-1 in patients with microangiopathy
Number of subjects: 33
Study 7988343 — intervention group
Group type: EXPERIMENTAL
Intervention: big endothelin-1 to endothelin-1 ratio in patients with microangiopathy
Number of subjects: 33
Study 7988343 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma levels of endothelin-1 and big endothelin-1
Number of subjects: 33
Study 3185647 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetics with neuropathy
Number of subjects: 30
Study 3185647 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetics without neuropathy
Number of subjects: 30
Study 3185647 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 30
Study 30227980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine (10% solution, 70 mg) applied over larynx and trachea
Number of subjects: 64
Study 30227980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swabs impregnated with 1 ml of 20 mg lidocaine solution
Number of subjects: 64
Study 30227980 — intervention group
Group type: COMPARATOR
Intervention: Control group (no application)
Number of subjects: 64
Study 31191096 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversally compliant ergometer (TCE)
Number of subjects: 11
Study 31191096 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal compliant ergometer (FCE)
Number of subjects: 11
Study 31191096 — intervention group
Group type: COMPARATOR
Intervention: Stable ergometer (STE)
Number of subjects: 11
Study 28804047 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume resistance training (HV)
Number of subjects: 33
Study 28804047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume resistance training (LV)
Number of subjects: 33
Study 28804047 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 33
Study 25169589 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (DCB) (3 µg/mm²)
Number of subjects: 131
Study 25169589 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (DES)
Number of subjects: 131
Study 23274779 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC/PEO gel treatment group
Number of subjects: 93
Study 23274779 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 20953883 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Glu/Arg (24 g dissolved in water twice daily for 8 weeks)
Number of subjects: 30
Study 20953883 — intervention group
Group type: COMPARATOR
Intervention: No supplement (Control)
Number of subjects: 30
Study 19894365 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal methylene blue (LMB) hydrogel
Number of subjects: 13
Study 17076319 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-coated composites
Number of subjects: 20
Study 17076319 — intervention group
Group type: COMPARATOR
Intervention: Untreated composite resins
Number of subjects: 20
Study 17076319 — intervention group
Group type: COMPARATOR
Intervention: HF-pretreated composites
Number of subjects: 20
Study 17076319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground surfaces of human enamel and dentin
Number of subjects: 20
Study 14658015 — intervention group
Group type: EXPERIMENTAL
Intervention: perindoprilat infusion
Number of subjects: 12
Study 14658015 — intervention group
Group type: COMPARATOR
Intervention: saline infusion (control)
Number of subjects: 12
Study 14658015 — intervention group
Group type: COMPARATOR
Intervention: diabetic patients
Number of subjects: 12
Study 11744411 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 87
Study 11744411 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 87
Study 11744411 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 87
Study 11744411 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 87
Study 9052106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressings for preventing catheter exit site infections
Number of subjects: 0
Study 9052106 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8096473 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min oxytocin infusion regimen
Number of subjects: 245
Study 8096473 — intervention group
Group type: COMPARATOR
Intervention: 15-min oxytocin infusion regimen
Number of subjects: 245
Study 3517235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesulergine
Number of subjects: 31
Study 3517235 — intervention group
Group type: COMPARATOR
Intervention: levodopa/benserazide (Madopar)
Number of subjects: 31
Study 30611272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithuanian version of the Child Perceptions Questionnaire (CPQ11-14)
Number of subjects: 307
Study 30396554 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly progesterone vaginal ring (VR)
Number of subjects: 1297
Study 30396554 — intervention group
Group type: COMPARATOR
Intervention: Daily progesterone gel
Number of subjects: 1297
Study 27379922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (7.5 mg) in combination with conventional diuretics (furosemide 20 mg and spironolactone 25 mg)
Number of subjects: 0
Study 27379922 — intervention group
Group type: COMPARATOR
Intervention: Control group (furosemide 20 mg and spironolactone 25 mg)
Number of subjects: 0
Study 27379922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (7.5 mg) in combination with conventional diuretics
Number of subjects: 0
Study 25079306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex‐PRESS
Number of subjects: 43
Study 25079306 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 43
Study 21997865 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) 250 mg twice daily for 5 days
Number of subjects: 100
Study 21997865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20561606 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet‐based cognitive behavioural treatment (iCBT) program
Number of subjects: 86
Study 20561606 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 86
Study 16938157 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg i.v.
Number of subjects: 76
Study 16938157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg i.v.
Number of subjects: 76
Study 16938157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16382664 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pyrithione zinc conditioning shampoo
Number of subjects: 40
Study 16382664 — intervention group
Group type: COMPARATOR
Intervention: 2% ketoconazole shampoo
Number of subjects: 40
Study 11953079 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA immunoabsorbent therapy
Number of subjects: 69
Study 11953079 — intervention group
Group type: COMPARATOR
Intervention: Common therapeutic group (control)
Number of subjects: 69